The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study
Abstract
Objective: We undertook this study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized anti–interleukin‐17 (anti–IL‐17) monoclonal antibody, in a first in‐human trial in rheumatoid arthritis (RA) patients taking oral disease‐modifying antirheumatic drugs (DMARDs). Methods: This randomized, double‐blind, placebo‐controlled study consisted of 2 parts. In part A, 20 patients received 1 intravenous (IV) dose of LY2439821 (0.06, 0.2, 0.6, or 2.0 mg/kg, escalating) or placebo followed by 8 weeks of evaluation. End points included safety, tolerability, and pharmacokinetics. In part B, 77 patients received 1 IV dose of LY2439821 (0.2, 0.6, or 2.0 mg/kg) or placebo every 2 weeks for a total of 5 doses, with a total evaluation period of 16 weeks. End points included safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy (Disease Activity Score in 28 joints [DAS28] and percentages of patients meeting American College of Rheumatology 20%, 50%, or 70% improvement criteria [achieving an ACR20, ACR50, or ACR70 response]). The primary efficacy end point was the DAS28 at week 10. Results: Baseline characteristics were similar across all groups. Changes in the DAS28 were significantly greater in the 0.2 mg/kg, 2.0 mg/kg, and all‐LY2439821–combined groups (−2.3, −2.4, and −2.3, respectively) than in the placebo group (−1.7) at week 10 ( P ≤ 0.05), and these differences were significant as early as week 1. Percentages of ACR20, ACR50, and ACR70 responses as well as improvements in the ACR core set of measures were greater in LY2439821‐treated patients than in placebo‐treated patients at multiple time points. There was no apparent dose‐response relationship in treatment‐emergent adverse events. Conclusion: LY2439821 added to oral DMARDs improved signs and symptoms of RA, with no strong adverse safety signal noted. This first evaluation of LY2439821 supports neutralization of IL‐17 as a potential novel goal for the treatment of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,640
Ye, P., Rodriguez, F. H., Kanaly, S., Stocking, K. L., Schurr, J., Schwarzenberger, P., Oliver, P., Huang, W., Zhang, P., Zhang, J., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.519 · Cited by 1,521
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice
Nakae, S., Nambu, A., Sudo, K., & Iwakura, Y. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6173 · Cited by 1,273
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
Guidelines for the management of rheumatoid arthritis: 2002 Update
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) · Arthritis & Rheumatism · doi:10.1002/art.10148 · Cited by 1,185
Guidelines for the management of rheumatoid arthritis: 2002 Update
Yood, R. A. (2002) · Cited by 1,090
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
Chabaud, M., Durand, J. M., Buchs, N., Fossiez, F., Page, G., Frappart, L., & Miossec, P. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199905)42:5<963::aid-anr15>3.0.co;2-e · Cited by 954
Hochberg, M. C., Chang, R. W., Dwosh, I., Lindsey, S., Pincus, T., & Wolfe, F. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350502 · Cited by 879
Guidelines for the Management of Rheumatoid Arthritis 2002 Update
Goolsby, M. J., & Newsome, G. (2002) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2002.tb00072.x · Cited by 855
Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H., & Maslinski, W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2832 · Cited by 580
Happel, K. I., Zheng, M., Young, E., Quinton, L. J., Lockhart, E., Ramsay, A. J., Shellito, J. E., Schurr, J. R., Bagby, G. J., Nelson, S., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4432 · Cited by 449
The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation
Kikly, K., Liu, L., Na, S., & Sedgwick, J. D. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.008 · Cited by 303
IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis?
Lubberts, E. (2008) · Cytokine · doi:10.1016/j.cyto.2007.09.014 · Cited by 289
Schwarzenberger, P., Huang, W., Ye, P., Oliver, P., Manuel, M., Zhang, Z., Bagby, G., Nelson, S., & Kolls, J. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4783 · Cited by 277
Bush, K. A., Farmer, K. M., Walker, J. S., & Kirkham, B. W. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10173 · Cited by 252
Joosten, L. A. B., Radstake, T. R. D. J., Lubberts, E., van den Bersselaar, L. A. M., van Riel, P. L. C. M., van Lent, P. L. E. M., Barrera, P., & van den Berg, W. B. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10814 · Cited by 124
Management of Rheumatoid Arthritis
Carswell, C., Perry, C. M., & Ibbotson, T. (2003) · Disease Management & Health Outcomes · doi:10.2165/00115677-200311110-00006 · Cited by 5
Cited by
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Functional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
Noack, M., & Miossec, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.12.004 · Cited by 932
Metadata
- Authors
- Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, P., & Sloan‐Lancaster, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-03-30
- Volume
- 62
- Issue
- 4
- Pages
- 929-939
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2076456688
- Cited by
- 451
- References
- 23
- FWCI
- 44.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.